{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T16:29:43Z","timestamp":1791563383148,"version":"4.3.4"},"reference-count":280,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2019,12,20]],"date-time":"2019-12-20T00:00:00Z","timestamp":1576800000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["G1000417"],"award-info":[{"award-number":["G1000417"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Statins are a cornerstone in the pharmacological prevention of cardiovascular disease. Although generally well tolerated, a small subset of patients experience statin-related myotoxicity (SRM). SRM is heterogeneous in presentation; phenotypes include the relatively more common myalgias, infrequent myopathies, and rare rhabdomyolysis. Very rarely, statins induce an anti-HMGCR positive immune-mediated necrotizing myopathy. Diagnosing SRM in clinical practice can be challenging, particularly for mild SRM that is frequently due to alternative aetiologies and the nocebo effect. Nevertheless, SRM can directly harm patients and lead to statin discontinuation\/non-adherence, which increases the risk of cardiovascular events. Several factors increase systemic statin exposure and predispose to SRM, including advanced age, concomitant medications, and the nonsynonymous variant, rs4149056, in SLCO1B1, which encodes the hepatic sinusoidal transporter, OATP1B1. Increased exposure of skeletal muscle to statins increases the risk of mitochondrial dysfunction, calcium signalling disruption, reduced prenylation, atrogin-1 mediated atrophy and pro-apoptotic signalling. Rare variants in several metabolic myopathy genes including CACNA1S, CPT2, LPIN1, PYGM and RYR1 increase myopathy\/rhabdomyolysis risk following statin exposure. The immune system is implicated in both conventional statin intolerance\/myotoxicity via LILRB5 rs12975366, and a strong association exists between HLA-DRB1*11:01 and anti-HMGCR positive myopathy. Epigenetic factors (miR-499-5p, miR-145) have also been implicated in statin myotoxicity. SRM remains a challenge to the safe and effective use of statins, although consensus strategies to manage SRM have been proposed. Further research is required, including stringent phenotyping of mild SRM through N-of-1 trials coupled to systems pharmacology omics- approaches to identify novel risk factors and provide mechanistic insight.<\/jats:p>","DOI":"10.3390\/jcm9010022","type":"journal-article","created":{"date-parts":[[2019,12,23]],"date-time":"2019-12-23T03:23:12Z","timestamp":1577071392000},"page":"22","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":178,"title":["Statin-Related Myotoxicity: A Comprehensive Review of Pharmacokinetic, Pharmacogenomic and Muscle Components"],"prefix":"10.3390","volume":"9","author":[{"given":"Richard Myles","family":"Turner","sequence":"first","affiliation":[{"name":"Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool L69 3GL, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7534-7266","authenticated-orcid":false,"given":"Munir","family":"Pirmohamed","sequence":"additional","affiliation":[{"name":"Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool L69 3GL, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2019,12,20]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"831","DOI":"10.2217\/pgs.12.25","article-title":"Pharmacogenetics of statins: Achievements, whole-genome analyses and future perspectives","volume":"13","author":"Postmus","year":"2012","journal-title":"Pharmacogenomics"},{"key":"ref_2","unstructured":"NHS Choices (2016, October 19). Nice Publishes New Draft Guidelines on Statins Use. Available online: http:\/\/www.nhs.uk\/news\/2014\/02February\/Pages\/NICE-publishes-new-draft-guidelines-on-statins-use.aspx."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.7164\/antibiotics.29.1346","article-title":"ML-236A, ML-236B, and ML-236C, new inhibitors of cholesterogenesis produced by penicillium citrinium","volume":"29","author":"Endo","year":"1976","journal-title":"J. Antibiot."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.atherosclerosissup.2004.08.033","article-title":"The origin of the statins","volume":"5","author":"Endo","year":"2004","journal-title":"Atherosclerosis. Suppl."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1749-8546-1-4","article-title":"Chinese red yeast rice (Monascus purpureus) for primary hyperlipidemia: A meta-analysis of randomized controlled trials","volume":"1","author":"Liu","year":"2006","journal-title":"Chin. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1006\/emyc.1995.1001","article-title":"Pleurotus fruiting bodies contain the inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme a reductase\u2014Lovastatin","volume":"19","author":"Cimerman","year":"1995","journal-title":"Exp. Mycol."},{"key":"ref_7","unstructured":"NICE (2019, October 23). Cardiovascular Disease: Risk Assessment and Reduction, Including Lipid Modification (Clinical Guideline 181). Available online: https:\/\/www.nice.org.uk\/guidance\/cg181."},{"key":"ref_8","unstructured":"National Statistics (2017, July 19). Prescriptions Dispensed in the Community, England 2004-14. Available online: http:\/\/content.digital.nhs.uk\/catalogue\/PUB17644\/pres-disp-com-eng-2004-14-rep.pdf."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1161\/ATVBAHA.108.179564","article-title":"The LDL receptor","volume":"29","author":"Goldstein","year":"2009","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_10","unstructured":"Rosenson, R.S. (2019, March 15). Statins: Actions, Side Effects, and Administration. Available online: https:\/\/www.uptodate.com\/contents\/statins-actions-side-effects-and-administration."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: A meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Trialists","year":"2010","journal-title":"Lancet"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"554","DOI":"10.4103\/2230-8210.163106","article-title":"Pleiotropic effects of statins","volume":"19","author":"Kavalipati","year":"2015","journal-title":"Indian J. Endocrinol. Metab."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.atherosclerosis.2019.11.033","article-title":"Atorvastatin inhibits pyroptosis through the lncrna nexn-as1\/nexn pathway in human vascular endothelial cells","volume":"293","author":"Wu","year":"2019","journal-title":"Atherosclerosis"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Gorabi, A.M., Kiaie, N., Hajighasemi, S., Banach, M., Penson, P.E., Jamialahmadi, T., and Sahebkar, A. (2019). Statin-induced nitric oxide signaling: Mechanisms and therapeutic implications. J. Clin. Med., 8.","DOI":"10.3390\/jcm8122051"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1056\/NEJMoa040583","article-title":"Intensive versus moderate lipid lowering with statins after acute coronary syndromes","volume":"350","author":"Cannon","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"21","DOI":"10.2478\/jtim-2018-0005","article-title":"Do statins induce or protect from acute kidney injury and chronic kidney disease: An update review in 2018","volume":"6","author":"Verdoodt","year":"2018","journal-title":"J. Transl. Int. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"16632","DOI":"10.1038\/s41598-019-53064-x","article-title":"Effect of different types of statins on kidney function decline and proteinuria: A network meta-analysis","volume":"9","author":"Esmeijer","year":"2019","journal-title":"Sci Rep"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1161\/HYPERTENSIONAHA.119.13219","article-title":"Statins reverse postpartum cardiovascular dysfunction in a rat model of preeclampsia","volume":"75","author":"Kraker","year":"2020","journal-title":"Hypertension"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"4048","DOI":"10.1021\/acs.molpharmaceut.5b00474","article-title":"Statin lactonization by uridine 5\u2032-diphospho-glucuronosyltransferases (UGTs)","volume":"12","author":"Schirris","year":"2015","journal-title":"Mol. Pharm."},{"key":"ref_20","first-page":"1369","article-title":"Lactonization is the critical first step in the disposition of the 3-hydroxy-3-methylglutaryl-coa reductase inhibitor atorvastatin","volume":"28","author":"Jacobsen","year":"2000","journal-title":"Drug Metab. Dispos. Biol. Fate Chem."},{"key":"ref_21","unstructured":"Pfizer Inc (2019, May 13). Lipitor- Atorvastatin Calcium Trihydrate Tablet, Film Coated. Highlights of Prescribing Information. Available online: http:\/\/labeling.pfizer.com\/ShowLabeling.aspx?id=587."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S1567-5688(10)71063-1","article-title":"Pitavastatin\u2014Pharmacological profile from early phase studies","volume":"11","author":"Catapano","year":"2010","journal-title":"Atheroscler. Suppl."},{"key":"ref_23","first-page":"755","article-title":"Metabolism and excretion studies in mouse after single and multiple oral doses of the 3-hydroxy-3-methylglutaryl-coa reductase inhibitor atorvastatin","volume":"26","author":"Black","year":"1998","journal-title":"Drug Metab. Dispos. Biol. Fate Chem."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1161\/CIRCRESAHA.109.203596","article-title":"Human skeletal muscle drug transporters determine local exposure and toxicity of statins","volume":"106","author":"Knauer","year":"2010","journal-title":"Circ. Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"639","DOI":"10.3109\/00498254.2011.562566","article-title":"Impact of SLCO1B1 (OATP1B1) and ABCG2 (BCRP) genetic polymorphisms and inhibition on LDL-C lowering and myopathy of statins","volume":"41","author":"Generaux","year":"2011","journal-title":"Xenobiotica"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0378-4347(99)00390-4","article-title":"Quantitation of cerivastatin and its seven acid and lactone biotransformation products in human serum by liquid chromatography-electrospray tandem mass spectrometry","volume":"736","author":"Jemal","year":"1999","journal-title":"J. Chromatogr. B Biomed. Sci. Appl."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"99","DOI":"10.2165\/00003088-200039020-00002","article-title":"Clinical pharmacokinetics of cerivastatin","volume":"39","author":"Muck","year":"2000","journal-title":"Clin. Pharmacokinet."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"192","DOI":"10.5414\/CPP39192","article-title":"The pharmacokinetics of cerivastatin in patients on chronic hemodialysis","volume":"39","author":"Muck","year":"2001","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"ref_29","unstructured":"Novartis (2019, July 07). Lescol (Fluvastatin Dosium)\u2014Highlights of Prescribing Information. Available online: https:\/\/www.pharma.us.novartis.com\/sites\/www.pharma.us.novartis.com\/files\/Lescol.pdf."},{"key":"ref_30","unstructured":"Merck & Co. (2019, December 19). Mevacor (Lovastatin) Tablets Description, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/019643s085lbl.pdf."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"463","DOI":"10.2165\/00003088-200847070-00003","article-title":"Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin","volume":"47","author":"Neuvonen","year":"2008","journal-title":"Clin. Pharmacokinet."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1080\/0049825021000017957","article-title":"Metabolic fate of pitavastatin, a new inhibitor of HMG-CoA reductase: Human UDP-Glucuronosyltransferase enzymes involved in lactonization","volume":"33","author":"Fujino","year":"2003","journal-title":"Xenobiotica"},{"key":"ref_33","unstructured":"Kowa Pharmaceuticals (2019, July 07). Livalo (Pitavastatin) Tablet\u2014Highlights of Prescribing Information, Available online: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/022363s008s009lbl.pdf."},{"key":"ref_34","unstructured":"Bristol-Myers Squibb Company (2019, July 07). Pravachol (Pravastatin) Tablets\u2014Highlights of Prescribing Information. Available online: http:\/\/packageinserts.bms.com\/pi\/pi_pravachol.pdf."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1093\/nar\/gkt1246","article-title":"The transformer database: Biotransformation of xenobiotics","volume":"42","author":"Hoffman","year":"2014","journal-title":"Nucleic Acids Res."},{"key":"ref_36","first-page":"169","article-title":"Quantification of pravastatin acid, lactone and isomers in human plasma by UHPLC-MS\/MS and its application to a pediatric pharmacokinetic study","volume":"1012\u20131013","author":"Gibson","year":"2016","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"key":"ref_37","unstructured":"Riedmaier, S. (2016, July 07). Pharmacogenetic Determinants of Atorvastatin Metabolism and Response (Dissertation). Available online: https:\/\/publikationen.uni-tuebingen.de\/xmlui\/bitstream\/handle\/10900\/49571\/pdf\/2011_Dissertation_Stephan_Riedmaier.pdf?sequence=1."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1124\/jpet.105.084830","article-title":"Bile salt export pump (BSEP\/ABCB11) can transport a nonbile acid substrate, pravastatin","volume":"314","author":"Hirano","year":"2005","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_39","first-page":"1055","article-title":"Zd4522\u2014An HMG-CoA reductase inhibitor free of metabolically mediated drug interactions: Metabolic studies in human in vitro systems (abstract 46)","volume":"40","author":"McCormick","year":"2000","journal-title":"J. Clin. Pharmacol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s00228-002-0508-8","article-title":"The effect of fluconazole on the pharmacokinetics of rosuvastatin","volume":"58","author":"Cooper","year":"2002","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/S0009-9236(02)17633-8","article-title":"Effect of itraconazole on the pharmacokinetics of rosuvastatin","volume":"73","author":"Cooper","year":"2003","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1002\/cpdd.135","article-title":"Effect of CYP2C19 polymorphism on the pharmacokinetics of rosuvastatin in healthy taiwanese subjects","volume":"4","author":"Finkelman","year":"2015","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"ref_43","unstructured":"AstraZeneca (2019, October 03). Crestor (Rosuvastatin Calcium Tablets)\u2014Highlights of Prescribing Information, Available online: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/021366s016lbl.pdf."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.tiv.2009.10.009","article-title":"Biliary efflux transporters involved in the clearance of rosuvastatin in sandwich culture of primary rat hepatocytes","volume":"24","author":"Jemnitz","year":"2010","journal-title":"Toxicol. In Vitro"},{"key":"ref_45","first-page":"46","article-title":"Pharmacokinetic of simvastatin study in malaysian subjects","volume":"3","author":"Alakhali","year":"2013","journal-title":"ISOR J. Pharm."},{"key":"ref_46","unstructured":"Merck & Co. (2019, October 17). Zocor (Simvastatin) Tablets\u2014Highlights of Prescribing Information. Available online: https:\/\/www.merck.com\/product\/usa\/pi_circulars\/z\/zocor\/zocor_pi.pdf."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1046\/j.1365-2125.2003.01833.x","article-title":"The human hepatic metabolism of simvastatin hydroxy acid is mediated primarily by CYP3A, and not CYP2D6","volume":"56","author":"Prueksaritanont","year":"2003","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1097\/FPC.0000000000000079","article-title":"CYP3A4*22 and CYP3A5*3 are associated with increased levels of plasma simvastatin concentrations in the cholesterol and pharmacogenetics study cohort","volume":"24","author":"Kitzmiller","year":"2014","journal-title":"Pharm. Genom."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1161\/CIRCGENETICS.113.000099","article-title":"Clinical and pharmacogenetic predictors of circulating atorvastatin and rosuvastatin concentration in routine clinical care","volume":"6","author":"DeGorter","year":"2013","journal-title":"Circ. Cardiovasc. Genet."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1016\/S0140-6736(16)31357-5","article-title":"Interpretation of the evidence for the efficacy and safety of statin therapy","volume":"388","author":"Collins","year":"2016","journal-title":"Lancet"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"373","DOI":"10.2165\/0129784-200808060-00004","article-title":"Statin adverse effects: A review of the literature and evidence for a mitochondrial mechanism","volume":"8","author":"Golomb","year":"2008","journal-title":"Am. J. Cardiovasc. Drugs"},{"key":"ref_52","unstructured":"The Electronic Medicines Compendium (eMC) (2019, July 17). Simvastatin 40 mg. Available online: https:\/\/www.medicines.org.uk\/emc\/product\/7167\/smpc."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1001\/archinternmed.2012.2171","article-title":"Effects of statins on energy and fatigue with exertion: Results from a randomized controlled trial","volume":"172","author":"Golomb","year":"2012","journal-title":"Arch. Intern. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1001\/jamainternmed.2014.2266","article-title":"Statins and physical activity in older men: The osteoporotic fractures in men study","volume":"174","author":"Lee","year":"2014","journal-title":"JAMA Intern. Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/j.jacl.2017.07.003","article-title":"The effects of statins on exercise and physical activity","volume":"11","author":"Noyes","year":"2017","journal-title":"J. Clin. Lipidol."},{"key":"ref_56","first-page":"150","article-title":"Statins and their effect on cognition: Let\u2019s clear up the confusion","volume":"148","author":"Gauthier","year":"2015","journal-title":"Can. Pharm. J. Rev. des Pharm. du Can."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1016\/j.jacc.2019.09.041","article-title":"Effects of statins on memory, cognition, and brain volume in the elderly","volume":"74","author":"Samaras","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s10557-005-5686-z","article-title":"Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients\u2014The primo study","volume":"19","author":"Bruckert","year":"2005","journal-title":"Cardiovasc. Drugs Ther."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"124","DOI":"10.3138\/ptc.2012-65","article-title":"Statin-induced rhabdomyolysis: A comprehensive review of case reports","volume":"66","author":"Mendes","year":"2014","journal-title":"Physiother. Can."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/j.amjmed.2011.12.013","article-title":"Adherence to drugs that prevent cardiovascular disease: Meta-analysis on 376,162 patients","volume":"125","author":"Naderi","year":"2012","journal-title":"Am. J. Med."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.jacl.2013.03.001","article-title":"Predictors of statin adherence, switching, and discontinuation in the usage survey: Understanding the use of statins in america and gaps in patient education","volume":"7","author":"Wei","year":"2013","journal-title":"J. Clin. Lipidol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1111\/bcp.12339","article-title":"Impact of statin adherence on cardiovascular disease and mortality outcomes: A systematic review","volume":"78","author":"Bhole","year":"2014","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.jacl.2016.12.007","article-title":"Investigating the prevalence, predictors, and prognosis of suboptimal statin use early after a non-st elevation acute coronary syndrome","volume":"11","author":"Turner","year":"2017","journal-title":"J. Clin. Lipidol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1038\/clpt.2014.121","article-title":"Phenotype standardization for statin-induced myotoxicity","volume":"96","author":"Alfirevic","year":"2014","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1161\/CIRCULATIONAHA.112.136101","article-title":"Effect of statins on skeletal muscle function","volume":"127","author":"Parker","year":"2013","journal-title":"Circulation"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1517\/14740338.2015.1039980","article-title":"Statin intolerance\u2014An attempt at a unified definition. Position paper from an international lipid expert panel","volume":"14","author":"Banach","year":"2015","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1093\/eurheartj\/ehv043","article-title":"Statin-associated muscle symptoms: Impact on statin therapy-european atherosclerosis society consensus panel statement on assessment, aetiology and management","volume":"36","author":"Stroes","year":"2015","journal-title":"Eur. Heart J."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"977","DOI":"10.4103\/2230-8210.122602","article-title":"Management of statin intolerance","volume":"17","author":"Raju","year":"2013","journal-title":"Indian J. Endocrinol. Metab."},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Elam, M.B., Majumdar, G., Mozhui, K., Gerling, I.C., Vera, S.R., Fish-Trotter, H., Williams, R.W., Childress, R.D., and Raghow, R. (2017). Patients experiencing statin-induced myalgia exhibit a unique program of skeletal muscle gene expression following statin re-challenge. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0181308"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"c2197","DOI":"10.1136\/bmj.c2197","article-title":"Unintended effects of statins in men and women in england and wales: Population based cohort study using the qresearch database","volume":"340","author":"Coupland","year":"2010","journal-title":"BMJ"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1161\/CIRCULATIONAHA.106.624890","article-title":"Risks associated with statin therapy: A systematic overview of randomized clinical trials","volume":"114","author":"Kashani","year":"2006","journal-title":"Circulation"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1517\/14740338.2011.540568","article-title":"Statin-induced myopathy: A review and update","volume":"10","author":"Abd","year":"2011","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1016\/j.jacc.2007.01.067","article-title":"Safety of aggressive lipid management","volume":"49","author":"Davidson","year":"2007","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_74","first-page":"205","article-title":"Withdrawal of cerivastatin from the world market","volume":"2","author":"Furberg","year":"2001","journal-title":"Curr. Control. Trials Cardiovasc. Med."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"g3306","DOI":"10.1136\/bmj.g3306","article-title":"Adverse effects of statins","volume":"348","author":"Godlee","year":"2014","journal-title":"BMJ"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1016\/S0140-6736(17)31075-9","article-title":"Adverse events associated with unblinded, but not with blinded, statin therapy in the anglo-scandinavian cardiac outcomes trial-lipid-lowering arm (ASCOT-LLA): A randomised double-blind placebo-controlled trial and its non-randomised non-blind extension phase","volume":"389","author":"Gupta","year":"2017","journal-title":"Lancet"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.atherosclerosis.2014.12.016","article-title":"A randomized trial of coenzyme Q10 in patients with confirmed statin myopathy","volume":"238","author":"Taylor","year":"2015","journal-title":"Atherosclerosis"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1001\/jama.2016.3608","article-title":"Efficacy and tolerability of evolocumab vs ezetimibe in patients with muscle-related statin intolerance: The GAUSS-3 randomized clinical trial","volume":"315","author":"Nissen","year":"2016","journal-title":"JAMA"},{"key":"ref_79","first-page":"129","article-title":"ABCB1 gene polymorphisms, ABCB1 haplotypes and ABCG2 c.421C > A are determinants of inter-subject variability in rosuvastatin pharmacokinetics","volume":"68","author":"Zhou","year":"2013","journal-title":"Die Pharm."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s00228-014-1801-z","article-title":"Impact of ABCG2 and SLCO1B1 polymorphisms on pharmacokinetics of rosuvastatin, atorvastatin and simvastatin acid in caucasian and asian subjects: A class effect?","volume":"71","author":"Birmingham","year":"2015","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1007\/s00228-002-0541-7","article-title":"Pharmacokinetics and pharmacodynamics of rosuvastatin in subjects with hepatic impairment","volume":"58","author":"Simonson","year":"2003","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1161\/01.CIR.0000032466.44170.44","article-title":"Acc\/aha\/nhlbi clinical advisory on the use and safety of statins","volume":"106","author":"Pasternak","year":"2002","journal-title":"Circulation"},{"key":"ref_83","first-page":"207","article-title":"Alcoholic myopathy: Pathophysiologic mechanisms and clinical implications","volume":"38","author":"Simon","year":"2017","journal-title":"Alcohol. Res."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1177\/00912700222011346","article-title":"Pharmacokinetics of fluvastatin in subjects with renal impairment and nephrotic syndrome","volume":"42","author":"Smith","year":"2002","journal-title":"J. Clin. Pharmacol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1016\/j.jacc.2009.04.053","article-title":"The SLCO1B1*5 genetic variant is associated with statin-induced side effects","volume":"54","author":"Voora","year":"2009","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1056\/NEJMoa0801936","article-title":"SLCO1B1 variants and statin-induced myopathy\u2014A genomewide study","volume":"359","author":"Link","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1002\/pds.1287","article-title":"Risk factors for statin-associated rhabdomyolysis","volume":"16","author":"Schech","year":"2007","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"ref_88","unstructured":"ClinRisk Ltd (2017, July 24). Qstatin\u20142014 Update Information. Available online: http:\/\/qintervention.org\/QStatin-2014-Update-Information.pdf."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1038\/clpt.2013.161","article-title":"SLCO1B1 genetic variant associated with statin-induced myopathy: A proof-of-concept study using the clinical practice research datalink","volume":"94","author":"Carr","year":"2013","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.jacl.2012.06.006","article-title":"Risk of hospitalized rhabdomyolysis associated with lipid-lowering drugs in a real-world clinical setting","volume":"7","author":"Cziraky","year":"2013","journal-title":"J. Clin. Lipidol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.trsl.2008.11.002","article-title":"Low serum 25 (OH) vitamin D levels (<32 ng\/ml) are associated with reversible myositis-myalgia in statin-treated patients","volume":"153","author":"Ahmed","year":"2009","journal-title":"Transl. Res."},{"key":"ref_92","first-page":"339","article-title":"Statin intolerance and vitamin d supplementation","volume":"7","author":"Khayznikov","year":"2015","journal-title":"N. Am. J. Med. Sci."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ijcard.2014.10.118","article-title":"Analysis of vitamin d levels in patients with and without statin-associated myalgia\u2014A systematic review and meta-analysis of 7 studies with 2420 patients","volume":"178","author":"Sahebkar","year":"2015","journal-title":"Int. J. Cardiol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1016\/S0026-0495(97)90218-3","article-title":"Lovastatin increases exercise-induced skeletal muscle injury","volume":"46","author":"Thompson","year":"1997","journal-title":"Metabolism"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1002\/mus.21817","article-title":"Statin-associated myopathy and its exacerbation with exercise","volume":"42","author":"Meador","year":"2010","journal-title":"Muscle Nerve"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1212\/WNL.62.4.670","article-title":"Statin-associated rhabdomyolysis triggered by grapefruit consumption","volume":"62","author":"Dreier","year":"2004","journal-title":"Neurology"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1016\/S0140-6736(07)60716-8","article-title":"The safety of statins in clinical practice","volume":"370","author":"Armitage","year":"2007","journal-title":"Lancet"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"869","DOI":"10.7326\/0003-4819-158-12-201306180-00004","article-title":"Statin toxicity from macrolide antibiotic coprescription: A population-based cohort study","volume":"158","author":"Patel","year":"2013","journal-title":"Ann. Intern. Med."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.clpt.2006.09.003","article-title":"Drug interactions with lipid-lowering drugs: Mechanisms and clinical relevance","volume":"80","author":"Neuvonen","year":"2006","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1056\/NEJM199509073331015","article-title":"Rhabdomyolysis from the coadministration of lovastatin and the antifungal agent itraconazole","volume":"333","author":"Lees","year":"1995","journal-title":"N. Engl. J. Med."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1093\/ajhp\/59.8.728","article-title":"Rhabdomyolysis due to probable interaction between simvastatin and ritonavir","volume":"59","author":"Cheng","year":"2002","journal-title":"Am. J. Health Syst. Pharm. AJHP Off. J. Am. Soc. Health Syst. Pharm."},{"key":"ref_102","first-page":"157","article-title":"Rhabdomyolysis after ezetimibe\/simvastatin therapy in an HIV-infected patient","volume":"1","author":"Chanson","year":"2008","journal-title":"NDT Plus"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1345\/aph.1D498","article-title":"Rhabdomyolysis in association with simvastatin and amiodarone","volume":"38","author":"Roten","year":"2004","journal-title":"Ann. Pharmacother."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.ejim.2004.11.016","article-title":"Severe myopathy induced by the co-administration of simvastatin and itraconazole","volume":"16","author":"Saliba","year":"2005","journal-title":"Eur. J. Intern. Med."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.2217\/pgs.13.135","article-title":"CYP2C9 and ABCG2 polymorphisms as risk factors for developing adverse drug reactions in renal transplant patients taking fluvastatin: A case-control study","volume":"14","author":"Bozina","year":"2013","journal-title":"Pharmacogenomics"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1124\/dmd.108.021410","article-title":"Involvement of multiple transporters in the hepatobiliary transport of rosuvastatin","volume":"36","author":"Kitamura","year":"2008","journal-title":"Drug Metab. Dispos."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1053\/j.gastro.2006.02.034","article-title":"Drug and bile acid transporters in rosuvastatin hepatic uptake: Function, expression, and pharmacogenetics","volume":"130","author":"Ho","year":"2006","journal-title":"Gastroenterology"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1038\/clpt.2012.163","article-title":"Understanding the critical disposition pathways of statins to assess drug-drug interaction risk during drug development: It\u2019s not just about OATP1B1","volume":"92","author":"Elsby","year":"2012","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/s41401-018-0013-y","article-title":"Effects of SLCO1B1 and gatm gene variants on rosuvastatin-induced myopathy are unrelated to high plasma exposure of rosuvastatin and its metabolites","volume":"40","author":"Bai","year":"2019","journal-title":"Acta Pharmacol. Sin."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1002\/cpt.1557","article-title":"Genome-wide association study of statin-induced myopathy in patients recruited using the UK clinical practice research datalink","volume":"106","author":"Carr","year":"2019","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_111","doi-asserted-by":"crossref","unstructured":"Floyd, J.S., Bloch, K.M., Brody, J.A., Maroteau, C., Siddiqui, M.K., Gregory, R., Carr, D.F., Molokhia, M., Liu, X., and Bis, J.C. (2019). Pharmacogenomics of statin-related myopathy: Meta-analysis of rare variants from whole-exome sequencing. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0218115"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.ahj.2013.01.025","article-title":"Lack of association between SLCO1B1 polymorphisms and clinical myalgia following rosuvastatin therapy","volume":"165","author":"Danik","year":"2013","journal-title":"Am. Heart J."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1097\/FPC.0000000000000018","article-title":"The SLCO1B1 c.521T > C polymorphism is associated with dose decrease or switching during statin therapy in the rotterdam study","volume":"24","author":"Peters","year":"2014","journal-title":"Pharm. Genom."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.atherosclerosis.2010.02.026","article-title":"Genetic involvement in statins induced myopathy. Preliminary data from an observational case-control study","volume":"211","author":"Puccetti","year":"2010","journal-title":"Atherosclerosis"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1097\/FPC.0b013e328343dd7d","article-title":"Cerivastatin, genetic variants, and the risk of rhabdomyolysis","volume":"21","author":"Marciante","year":"2011","journal-title":"Pharm. Genom."},{"key":"ref_116","first-page":"721","article-title":"Association between SLCO1B1 T521C polymorphism and risk of statin-induced myopathy: A meta-analysis","volume":"18","author":"Xiang","year":"2018","journal-title":"Pharm. J."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s00228-014-1661-6","article-title":"Association between statin-induced creatine kinase elevation and genetic polymorphisms in SLCO1B1, ABCB1 and ABCG2","volume":"70","author":"Ferrari","year":"2014","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.clpt.2005.08.003","article-title":"The role of common variants of ABCB1, CYP3A4, and CYP3A5 genes in lipid-lowering efficacy and safety of simvastatin treatment","volume":"78","author":"Fiegenbaum","year":"2005","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jacl.2011.01.001","article-title":"The C3435T polymorphism in ABCB1 influences atorvastatin efficacy and muscle symptoms in a high-risk vascular cohort","volume":"5","author":"Hoenig","year":"2011","journal-title":"J. Clin. Lipidol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"803","DOI":"10.2217\/pgs.15.47","article-title":"ABCG2 gene polymorphisms as risk factors for atorvastatin adverse reactions: A case-control study","volume":"16","author":"Simic","year":"2015","journal-title":"Pharmacogenomics"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/pds.1866","article-title":"Influence of genetic variation in CYP3A4 and ABCB1 on dose decrease or switching during simvastatin and atorvastatin therapy","volume":"19","author":"Becker","year":"2010","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1097\/FPC.0b013e328012d0a9","article-title":"CYP2D6*4 polymorphism is associated with statin-induced muscle effects","volume":"17","author":"Frudakis","year":"2007","journal-title":"Pharm. Genom."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/S0009-9236(01)25429-0","article-title":"Association of polymorphism in the cytochrome CYP2D6 and the efficacy and tolerability of simvastatin","volume":"70","author":"Mulder","year":"2001","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1097\/01213011-200506000-00007","article-title":"Relative impact of CYP3A genotype and concomitant medication on the severity of atorvastatin-induced muscle damage","volume":"15","author":"Wilke","year":"2005","journal-title":"Pharm. Genom."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.phrs.2006.12.009","article-title":"Tolerability of statins is not linked to CYP450 polymorphisms, but reduced CYP2D6 metabolism improves cholesteraemic response to simvastatin and fluvastatin","volume":"55","author":"Zuccaro","year":"2007","journal-title":"Pharmacol. Res."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/nature12508","article-title":"A statin-dependent qtl for gatm expression is associated with statin-induced myopathy","volume":"502","author":"Mangravite","year":"2013","journal-title":"Nature"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1476-511X-6-7","article-title":"Genetic determinants of statin intolerance","volume":"6","author":"Oh","year":"2007","journal-title":"Lipids Health Dis."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.atherosclerosis.2011.07.007","article-title":"Mechanisms of statin-induced myalgia assessed by physiogenomic associations","volume":"218","author":"Ruano","year":"2011","journal-title":"Atherosclerosis"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1002\/mus.20567","article-title":"Genetic risk factors associated with lipid-lowering drug-induced myopathies","volume":"34","author":"Vladutiu","year":"2006","journal-title":"Muscle Nerve"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1001\/archinte.166.14.1519","article-title":"Presymptomatic neuromuscular disorders disclosed following statin treatment","volume":"166","author":"Tsivgoulis","year":"2006","journal-title":"Arch. Intern. Med."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1056\/NEJMc0908215","article-title":"Neuromuscular symptoms and elevated creatine kinase after statin withdrawal","volume":"362","author":"Mohr","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"478","DOI":"10.7326\/0003-4819-152-7-201004060-00025","article-title":"Another side to statin-related side effects","volume":"152","author":"Knoblauch","year":"2010","journal-title":"Ann. Intern. Med."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1111\/j.1365-2796.2005.01515.x","article-title":"Statin-disclosed acid maltase deficiency","volume":"258","author":"Voermans","year":"2005","journal-title":"J. Intern. Med."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.ajhg.2008.09.002","article-title":"Mutations in lpin1 cause recurrent acute myoglobinuria in childhood","volume":"83","author":"Zeharia","year":"2008","journal-title":"Am. J. Hum. Genet."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.ymgme.2011.07.001","article-title":"Genetic risk for malignant hyperthermia in non-anesthesia-induced myopathies","volume":"104","author":"Vladutiu","year":"2011","journal-title":"Mol. Genet. Metab."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.2217\/pgs-2018-0106","article-title":"Ryr1 and cacna1s genetic variants identified with statin-associated muscle symptoms","volume":"19","author":"Isackson","year":"2018","journal-title":"Pharmacogenomics"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1002\/mus.24541","article-title":"Clinical and genetic associations of autoantibodies to 3-hydroxy-3-methyl-glutaryl-coenzyme a reductase in patients with immune-mediated myositis and necrotizing myopathy","volume":"52","author":"Limaye","year":"2015","journal-title":"Muscle Nerve"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1002\/acr.21671","article-title":"Increased frequency of drb1*11:01 in anti-hydroxymethylglutaryl-coenzyme a reductase-associated autoimmune myopathy","volume":"64","author":"Mammen","year":"2012","journal-title":"Arthritis Care Res."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"3569","DOI":"10.1093\/eurheartj\/ehx467","article-title":"A common missense variant of LILRB5 is associated with statin intolerance and myalgia","volume":"38","author":"Siddiqui","year":"2017","journal-title":"Eur. Heart J."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1002\/mus.20871","article-title":"Physiogenomic association of statin-related myalgia to serotonin receptors","volume":"36","author":"Ruano","year":"2007","journal-title":"Muscle Nerve"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1002\/mus.22115","article-title":"Association of common variants in the human eyes shut ortholog (EYS) with statin-induced myopathy: Evidence for additional functions of EYS","volume":"44","author":"Isackson","year":"2011","journal-title":"Muscle Nerve"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1038\/nrd1851","article-title":"Predicting in vivo drug interactions from in vitro drug discovery data","volume":"4","author":"Wienkers","year":"2005","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1093\/hmg\/ddt588","article-title":"Quantifying rare, deleterious variation in 12 human cytochrome P450 drug-metabolism genes in a large-scale exome dataset","volume":"23","author":"Gordon","year":"2014","journal-title":"Hum. Mol. Genet."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1080\/00498250802334391","article-title":"Contribution of cytochrome P450 3A4 and 3A5 to the metabolism of atorvastatin","volume":"38","author":"Park","year":"2008","journal-title":"Xenobiotica"},{"key":"ref_145","first-page":"274","article-title":"Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs","volume":"11","author":"Wang","year":"2011","journal-title":"Pharm. J."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1097\/FPC.0000000000000183","article-title":"CYP3A4 intronic snp rs35599367 (CYP3A4*22) alters RNA splicing","volume":"26","author":"Wang","year":"2016","journal-title":"Pharm. Genom."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"D710","DOI":"10.1093\/nar\/gkv1157","article-title":"Ensembl 2016","volume":"44","author":"Yates","year":"2016","journal-title":"Nucleic Acids Res."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1038\/clpt.2011.336","article-title":"PPARA: A novel genetic determinant of CYP3A4 in vitro and in vivo","volume":"91","author":"Klein","year":"2012","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/gim.2016.33","article-title":"Rare genetic variants in cellular transporters, metabolic enzymes, and nuclear receptors can be important determinants of interindividual differences in drug response","volume":"19","author":"Kozyra","year":"2017","journal-title":"Genet. Med."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/clpt.2014.55","article-title":"Identification of the effect of multiple polymorphisms on the pharmacokinetics of simvastatin and simvastatin acid using a population-modeling approach","volume":"96","author":"Tsamandouras","year":"2014","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2217\/pgs.12.187","article-title":"CYP3A4*22: Promising newly identified CYP3A4 variant allele for personalizing pharmacotherapy","volume":"14","author":"Elens","year":"2013","journal-title":"Pharmacogenomics"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1592\/phco.31.10.942","article-title":"Effect of cytochrome P450 3A5 genotype on atorvastatin pharmacokinetics and its interaction with clarithromycin","volume":"31","author":"Shin","year":"2011","journal-title":"Pharmacotherapy"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1177\/0091270006295063","article-title":"Effect of polymorphic CYP3A5 genotype on the single-dose simvastatin pharmacokinetics in healthy subjects","volume":"47","author":"Kim","year":"2007","journal-title":"J. Clin. Pharmacol."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"P18","DOI":"10.1016\/j.clpt.2003.11.067","article-title":"The effect of CYP2D6 genotype on the pharmacokinetics of lovastatin in Chinese subjects","volume":"75","author":"Yin","year":"2004","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1007\/s00228-011-1202-5","article-title":"Impact of CYP2D6 polymorphisms on the pharmacokinetics of lovastatin in Chinese subjects","volume":"68","author":"Yin","year":"2012","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1097\/FPC.0000000000000176","article-title":"Impact of CYP2D6, CYP3A5, CYP2C19, CYP2A6, SLCO1B1, ABCB1, and ABCG2 gene polymorphisms on the pharmacokinetics of simvastatin and simvastatin acid","volume":"25","author":"Choi","year":"2015","journal-title":"Pharm. Genom."},{"key":"ref_157","first-page":"1191","article-title":"In vitro Metabolism of Simvastatin in Humans [sbt]Identification of metabolizing enzymes and effect of the drug on hepatic P450s","volume":"25","author":"Prueksaritanont","year":"1997","journal-title":"Drug Metab. Dispos."},{"key":"ref_158","first-page":"488","article-title":"In vitro metabolism and interaction studies with celecoxib and lovastatin","volume":"64","author":"Iyer","year":"2004","journal-title":"Cancer Res."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/S0009-9236(03)00121-8","article-title":"Influence of CYP2C9 polymorphisms on the pharmacokinetics and cholesterol-lowering activity of (\u2212)-3s,5r-fluvastatin and (+)-3r,5s-fluvastatin in healthy volunteers","volume":"74","author":"Kirchheiner","year":"2003","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1097\/00008571-200204000-00010","article-title":"Cytochrome P450 2C9 polymorphisms: A comprehensive review of the in-vitro and human data","volume":"12","author":"Lee","year":"2002","journal-title":"Pharmacogenetics"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/clpt.2009.181","article-title":"UDP-Glucuronosyltransferase (UGT) polymorphisms affect atorvastatin lactonization in vitro and in vivo","volume":"87","author":"Riedmaier","year":"2010","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1023\/A:1018923325359","article-title":"The interconversion kinetics, equilibrium, and solubilities of the lactone and hydroxyacid forms of the HMG-CoA reductase inhibitor, CI-981","volume":"10","author":"Kearney","year":"1993","journal-title":"Pharm. Res."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1124\/dmd.105.006650","article-title":"Acyl-coenzyme a formation of simvastatin in mouse liver preparations","volume":"34","author":"Li","year":"2006","journal-title":"Drug Metab. Dispos."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1124\/dmd.30.5.505","article-title":"Glucuronidation of statins in animals and humans: A novel mechanism of statin lactonization","volume":"30","author":"Prueksaritanont","year":"2002","journal-title":"Drug Metab. Dispos."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.ejps.2007.12.009","article-title":"Statin induced myotoxicity: The lactone forms are more potent than the acid forms in human skeletal muscle cells in vitro","volume":"33","author":"Skottheim","year":"2008","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1097\/FPC.0b013e3283544085","article-title":"The UGT1A3*2 polymorphism affects atorvastatin lactonization and lipid-lowering effect in healthy volunteers","volume":"22","author":"Cho","year":"2012","journal-title":"Pharm. Genom."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s40291-013-0031-x","article-title":"UGT1A1*28 is associated with decreased systemic exposure of atorvastatin lactone","volume":"17","author":"Stormo","year":"2013","journal-title":"Mol. Diagn. Ther."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/gm405","article-title":"Genetics is a major determinant of expression of the human hepatic uptake transporter OATP1B1, but not of OATP1B3 and OATP2B1","volume":"5","author":"Nies","year":"2013","journal-title":"Genome Med."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1097\/FPC.0000000000000148","article-title":"SLCO1B1 polymorphism markedly affects the pharmacokinetics of lovastatin acid","volume":"25","author":"Tornio","year":"2015","journal-title":"Pharm. Genom."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1097\/01.fpc.0000230416.82349.90","article-title":"SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid","volume":"16","author":"Pasanen","year":"2006","journal-title":"Pharm. Genom."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/sj.clpt.6100190","article-title":"SLCO1B1 (OATP1B1, an uptake transporter) and ABCG2 (BCRP, an efflux transporter) variant alleles and pharmacokinetics of pitavastatin in healthy volunteers","volume":"82","author":"Ieiri","year":"2007","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1038\/sj.clpt.6100220","article-title":"Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin","volume":"82","author":"Pasanen","year":"2007","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.clpt.2006.06.010","article-title":"SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin","volume":"80","author":"Niemi","year":"2006","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_174","first-page":"233","article-title":"Differential effect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatin","volume":"12","author":"Brunham","year":"2012","journal-title":"Pharm. J."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1038\/clpt.2010.255","article-title":"Common nonsynonymous substitutions in SLCO1B1 predispose to statin intolerance in routinely treated individuals with type 2 diabetes: A Go-DARTS study","volume":"89","author":"Donnelly","year":"2011","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1007\/s00228-017-2318-z","article-title":"SLCO1B1 521T > C polymorphism associated with rosuvastatin-induced myotoxicity in Chinese coronary artery disease patients: A nested case\u2014Control study","volume":"73","author":"Liu","year":"2017","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s00228-011-1125-1","article-title":"SLCO1B1 haplotypes are not associated with atorvastatin-induced myalgia in brazilian patients with familial hypercholesterolemia","volume":"68","author":"Santos","year":"2012","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_178","first-page":"1454","article-title":"SLCO1B1 polymorphism is not associated with risk of statin-induced myalgia\/myopathy in a czech population","volume":"21","author":"Hubacek","year":"2015","journal-title":"Med. Sci. Monit. Int. Med. J. Exp. Clin. Res."},{"key":"ref_179","unstructured":"Food and Drug Administration (2019, December 19). FDA Drug Safety Communication: New restrictions, contraindications, and dose limitations for Zocor (simvastatin) to reduce the risk of muscle injury, Available online: http:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-new-restrictions-contraindications-and-dose-limitations-zocor."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/clpt.2014.125","article-title":"The clinical pharmacogenetics implementation consortium guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update","volume":"96","author":"Ramsey","year":"2014","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_181","unstructured":"KNMP (2019, July 17). Pharmacogenetic Recommendations. Available online: https:\/\/www.knmp.nl\/patientenzorg\/medicatiebewaking\/farmacogenetica\/pharmacogenetics-1\/pharmacogenetics."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"35","DOI":"10.5497\/wjp.v2.i1.35","article-title":"Drug-transporter interaction testing in drug discovery and development","volume":"2","author":"Krajcsi","year":"2013","journal-title":"World J. Pharmacol."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.reprotox.2006.01.007","article-title":"P-glycoprotein in the placenta: Expression, localization, regulation and function","volume":"22","author":"Pavek","year":"2006","journal-title":"Reprod. Toxicol."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1007\/s11095-008-9537-z","article-title":"BCRP\/ABCG2 in the placenta: Expression, function and regulation","volume":"25","author":"Mao","year":"2008","journal-title":"Pharm. Res."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/clpt.2008.25","article-title":"ABCB1 haplotypes differentially affect the pharmacokinetics of the acid and lactone forms of simvastatin and atorvastatin","volume":"84","author":"Keskitalo","year":"2008","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1124\/dmd.111.043018","article-title":"Cyclosporine A- and Tacrolimus-Mediated Inhibition of CYP3A4 and CYP3A5 In Vitro","volume":"40","author":"Amundsen","year":"2012","journal-title":"Drug Metab. Dispos."},{"key":"ref_187","unstructured":"Zhang, L. (2017, July 18). Transporter-Mediated Drug-Drug Interactions (DDIs), Available online: https:\/\/www.fda.gov\/downloads\/Drugs\/DevelopmentApprovalProcess\/DevelopmentResources\/DrugInteractionsLabeling\/UCM207267.pdf."},{"key":"ref_188","unstructured":"Merck Sharp & Dohme Corp (2019, November 07). Prevymis (Letermovir) Highlights of Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/209939Orig1s000,209940Orig1s000lbl.pdf."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s40256-017-0222-7","article-title":"Recommendations for managing drug-drug interactions with statins and HIV medications","volume":"17","author":"Wiggins","year":"2017","journal-title":"Am. J. Cardiovasc. Drugs"},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"e468","DOI":"10.1161\/CIR.0000000000000456","article-title":"Recommendations for management of clinically significant drug-drug interactions with statins and select agents used in patients with cardiovascular disease: A scientific statement from the american heart association","volume":"134","author":"Wiggins","year":"2016","journal-title":"Circulation"},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1016\/j.bbrc.2005.10.108","article-title":"Simvastatin induces impairment in skeletal muscle while heart is protected","volume":"338","author":"Sirvent","year":"2005","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.cmet.2015.08.002","article-title":"Statin-induced myopathy is associated with mitochondrial complex iii inhibition","volume":"22","author":"Schirris","year":"2015","journal-title":"Cell Metab."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.amjcard.2011.08.045","article-title":"Effect of statins on creatine kinase levels before and after a marathon run","volume":"109","author":"Parker","year":"2012","journal-title":"Am. J. Cardiol."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1111\/j.1365-2125.2003.02044.x","article-title":"Professional athletes suffering from familial hypercholesterolaemia rarely tolerate statin treatment because of muscular problems","volume":"57","author":"Sinzinger","year":"2004","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1097\/JES.0b013e31826c169e","article-title":"Effect of statins on skeletal muscle: Exercise, myopathy, and muscle outcomes","volume":"40","author":"Parker","year":"2012","journal-title":"Exerc. Sport Sci. Rev."},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1152\/japplphysiol.00654.2015","article-title":"Influence of statins on distinct circulating micrornas during prolonged aerobic exercise","volume":"120","author":"Min","year":"2016","journal-title":"J. Appl. Physiol."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.jacbts.2019.03.012","article-title":"A mechanism for statin-induced susceptibility to myopathy","volume":"4","author":"Lotteau","year":"2019","journal-title":"JACC Basic Transl. Sci."},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1002\/mus.23309","article-title":"Mitochondria of trained skeletal muscle are protected from deleterious effects of statins","volume":"46","author":"Bouitbir","year":"2012","journal-title":"Muscle Nerve"},{"key":"ref_199","unstructured":"Rosenson, R.S., and Baker, S.K. (2019, October 02). Statin Muscle-Related Adverse Events. Available online: https:\/\/www.uptodate.com\/contents\/statin-muscle-related-adverse-events."},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1093\/cvr\/cvy119","article-title":"Role of genetics in the prediction of statin-associated muscle symptoms and optimization of statin use and adherence","volume":"114","author":"Brunham","year":"2018","journal-title":"Cardiovasc. Res."},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1159\/000101287","article-title":"Statins provoking melas syndrome","volume":"57","author":"Thomas","year":"2007","journal-title":"Eur. Neurol."},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.pediatrneurol.2008.09.002","article-title":"Myotoxicity of lipid-lowering agents in a teenager with melas mutation","volume":"39","author":"Tay","year":"2008","journal-title":"Pediatr. Neurol."},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1212\/01.WNL.0000145708.03876.C3","article-title":"Statin-associated exacerbation of myasthenia gravis","volume":"63","author":"Cartwright","year":"2004","journal-title":"Neurology"},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1136\/bmj.308.6928.588","article-title":"Myxoedema revealed by simvastatin induced myopathy","volume":"308","author":"Briston","year":"1994","journal-title":"BMJ"},{"key":"ref_205","first-page":"198","article-title":"Pravastatin-associated myopathy. Report of a case","volume":"86","author":"Scalvini","year":"1995","journal-title":"Recent. Progress. Med."},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1002\/mus.20575","article-title":"Sporadic rippling muscle disease unmasked by simvastatin","volume":"34","author":"Baker","year":"2006","journal-title":"Muscle Nerve"},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/0002-9343(93)90129-D","article-title":"Simvastatin-induced rhabdomyolysis followed by a melas syndrome","volume":"94","author":"Chariot","year":"1993","journal-title":"Am. J. Med."},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1002\/(SICI)1097-4598(199606)19:6<764::AID-MUS12>3.0.CO;2-L","article-title":"Impairment of muscle mitochondrial oxidative metabolism in mcardles\u2019s disease","volume":"19","author":"Argov","year":"1996","journal-title":"Muscle Nerve"},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1021\/tx400409c","article-title":"Drug-induced rhabdomyolysis: From systems pharmacology analysis to biochemical flux","volume":"27","author":"Hur","year":"2014","journal-title":"Chem. Res. Toxicol."},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.clpt.2006.02.014","article-title":"Exposure of atorvastatin is unchanged but lactone and acid metabolites are increased several-fold in patients with atorvastatin-induced myopathy","volume":"79","author":"Hermann","year":"2006","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1007\/s00228-017-2224-4","article-title":"The effects of 2 weeks of statin treatment on mitochondrial respiratory capacity in middle-aged males: The lifestat study","volume":"73","author":"Asping","year":"2017","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.freeradbiomed.2011.10.449","article-title":"Simvastatin impairs adp-stimulated respiration and increases mitochondrial oxidative stress in primary human skeletal myotubes","volume":"52","author":"Kwak","year":"2012","journal-title":"Free Radic. Biol. Med."},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1021\/cb200206w","article-title":"A small-molecule screening strategy to identify suppressors of statin myopathy","volume":"6","author":"Wagner","year":"2011","journal-title":"ACS Chem. Biol."},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/nbt1387","article-title":"Large-scale chemical dissection of mitochondrial function","volume":"26","author":"Wagner","year":"2008","journal-title":"Nat. Biotechnol."},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1016\/j.xphs.2017.04.005","article-title":"Association of miR-145 with statin-induced skeletal muscle toxicity in human rhabdomyosarcoma RD cells","volume":"106","author":"Saito","year":"2017","journal-title":"J. Pharm. Sci."},{"key":"ref_216","first-page":"16","article-title":"Coenzyme Q10 and statin-induced mitochondrial dysfunction","volume":"10","author":"Deichmann","year":"2010","journal-title":"Ochsner J."},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/biof.155","article-title":"Primary and secondary CoQ10 deficiencies in humans","volume":"37","author":"Quinzii","year":"2011","journal-title":"Biofactors"},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1001\/archneur.62.11.1709","article-title":"Muscle coenzyme Q10 level in statin-related myopathy","volume":"62","author":"Lamperti","year":"2005","journal-title":"Arch. Neurol."},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/j.bcp.2009.12.007","article-title":"Effect of simvastatin on cholesterol metabolism in C2C12 myotubes and HepG2 cells, and consequences for statin-induced myopathy","volume":"79","author":"Mullen","year":"2010","journal-title":"Biochem. Pharmacol."},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1056\/NEJMc0800582","article-title":"Early coenzyme Q10 supplementation in primary coenzyme Q10 deficiency","volume":"358","author":"Montini","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.mayocp.2014.08.021","article-title":"Effects of coenzyme Q10 on statin-induced myopathy: A meta-analysis of randomized controlled trials","volume":"90","author":"Banach","year":"2015","journal-title":"Mayo Clin. Proc."},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1111\/bcp.12360","article-title":"Mechanisms and assessment of statin-related muscular adverse effects","volume":"78","author":"Schaeffeler","year":"2014","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1006\/taap.1997.8174","article-title":"HMG CoA reductase inhibitor-induced myotoxicity: Pravastatin and lovastatin inhibit the geranylgeranylation of low-molecular-weight proteins in neonatal rat muscle cell culture","volume":"145","author":"Flint","year":"1997","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"ref_224","doi-asserted-by":"crossref","first-page":"4087","DOI":"10.1096\/fj.07-8713com","article-title":"Rab-small gtpases are involved in fluvastatin and pravastatin-induced vacuolation in rat skeletal myofibers","volume":"21","author":"Sakamoto","year":"2007","journal-title":"FASEB J."},{"key":"ref_225","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1254\/jphs.08238FP","article-title":"Possible mechanisms underlying statin-induced skeletal muscle toxicity in l6 fibroblasts and in rats","volume":"109","author":"Itagaki","year":"2009","journal-title":"J. Pharmacol. Sci."},{"key":"ref_226","doi-asserted-by":"crossref","first-page":"17747","DOI":"10.1038\/s41598-019-53700-6","article-title":"Statin-specific inhibition of Rab-GTPase regulates cPKC-mediated IKs internalization","volume":"9","author":"Ronzier","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_227","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1096\/fj.08-128843","article-title":"Statin-induced muscle damage and atrogin-1 induction is the result of a geranylgeranylation defect","volume":"23","author":"Cao","year":"2009","journal-title":"FASEB J."},{"key":"ref_228","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1016\/j.bbamcr.2011.07.019","article-title":"Susceptibility to simvastatin-induced toxicity is partly determined by mitochondrial respiration and phosphorylation state of Akt","volume":"1813","author":"Mullen","year":"2011","journal-title":"Biochim. Biophys. Acta Mol. Cell Res."},{"key":"ref_229","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1016\/j.bbamcr.2015.04.010","article-title":"The AKT\/mTOR signaling pathway plays a key role in statin-induced myotoxicity","volume":"1853","author":"Bonifacio","year":"2015","journal-title":"Biochim. Biophys. Acta Mol. Cell Res."},{"key":"ref_230","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1002\/path.2018","article-title":"Statin therapy induces ultrastructural damage in skeletal muscle in patients without myalgia","volume":"210","author":"Draeger","year":"2006","journal-title":"J. Pathol."},{"key":"ref_231","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_232","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.jacl.2015.08.006","article-title":"Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The odyssey alternative randomized trial","volume":"9","author":"Moriarty","year":"2015","journal-title":"J. Clin. Lipidol."},{"key":"ref_233","doi-asserted-by":"crossref","first-page":"14440","DOI":"10.1073\/pnas.251541198","article-title":"Atrogin-1, a muscle-specific f-box protein highly expressed during muscle atrophy","volume":"98","author":"Gomes","year":"2001","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_234","first-page":"3940","article-title":"The muscle-specific ubiquitin ligase atrogin-1\/mafbx mediates statin-induced muscle toxicity","volume":"117","author":"Hanai","year":"2007","journal-title":"J. Clin. Investig."},{"key":"ref_235","doi-asserted-by":"crossref","first-page":"2494","DOI":"10.1016\/S0006-3495(00)76491-5","article-title":"Ryr1 and ryr3 have different roles in the assembly of calcium release units of skeletal muscle","volume":"79","author":"Protasi","year":"2000","journal-title":"Biophys. J."},{"key":"ref_236","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1002\/humu.20356","article-title":"Mutations in ryr1 in malignant hyperthermia and central core disease","volume":"27","author":"Robinson","year":"2006","journal-title":"Hum. Mutat."},{"key":"ref_237","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/1750-1172-2-31","article-title":"Multi-minicore disease","volume":"2","author":"Jungbluth","year":"2007","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_238","doi-asserted-by":"crossref","first-page":"E11","DOI":"10.1503\/cmaj.081785","article-title":"Association between statin-associated myopathy and skeletal muscle damage","volume":"181","author":"Mohaupt","year":"2009","journal-title":"CMAJ"},{"key":"ref_239","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1161\/01.CIR.103.4.485","article-title":"Mutations of the cardiac ryanodine receptor (RYR2) gene in familial polymorphic ventricular tachycardia","volume":"103","author":"Laitinen","year":"2001","journal-title":"Circulation"},{"key":"ref_240","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.cmet.2015.03.003","article-title":"Gatm polymorphism associated with the risk for statin-induced myopathy does not replicate in case-control analysis of 715 dyslipidemic individuals","volume":"21","author":"Luzum","year":"2015","journal-title":"Cell Metab."},{"key":"ref_241","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1038\/nature13628","article-title":"Gatm gene variants and statin myopathy risk","volume":"513","author":"Carr","year":"2014","journal-title":"Nature"},{"key":"ref_242","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1038\/nature13629","article-title":"Gatm locus does not replicate in rhabdomyolysis study","volume":"513","author":"Floyd","year":"2014","journal-title":"Nature"},{"key":"ref_243","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1161\/CIRCGENETICS.113.000395","article-title":"CKM and LILRB5 are associated with serum levels of creatine kinase","volume":"7","author":"Dube","year":"2014","journal-title":"Circ. Cardiovasc. Genet."},{"key":"ref_244","unstructured":"ClinicalTrials.gov (2019, July 24). Statin Immune Study (Immunostat) nct02984293, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02984293."},{"key":"ref_245","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.immuni.2016.01.009","article-title":"Poor repair of skeletal muscle in aging mice reflects a defect in local, interleukin-33-dependent accumulation of regulatory t cells","volume":"44","author":"Kuswanto","year":"2016","journal-title":"Immunity"},{"key":"ref_246","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.nmd.2006.10.007","article-title":"Progressive myopathy with up-regulation of MHC-I associated with statin therapy","volume":"17","author":"Needham","year":"2007","journal-title":"Neuromuscul. Disord."},{"key":"ref_247","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/mus.21486","article-title":"Immune-mediated necrotizing myopathy associated with statins","volume":"41","author":"Katzberg","year":"2010","journal-title":"Muscle Nerve"},{"key":"ref_248","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1002\/art.27572","article-title":"A novel autoantibody recognizing 200-kd and 100-kd proteins is associated with an immune-mediated necrotizing myopathy","volume":"62","author":"Hong","year":"2010","journal-title":"Arthritis Rheum."},{"key":"ref_249","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1002\/art.30156","article-title":"Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme a reductase (HMGCR) in patients with statin-associated autoimmune myopathy","volume":"63","author":"Mammen","year":"2011","journal-title":"Arthritis Rheum."},{"key":"ref_250","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1056\/NEJMra1515161","article-title":"Statin-associated autoimmune myopathy","volume":"374","author":"Mammen","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_251","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s11926-018-0732-6","article-title":"Immune-mediated necrotizing myopathy","volume":"20","author":"Mammen","year":"2018","journal-title":"Curr. Rheumatol. Rep."},{"key":"ref_252","doi-asserted-by":"crossref","first-page":"4087","DOI":"10.1002\/art.34673","article-title":"Antibody levels correlate with creatine kinase levels and strength in anti-3-hydroxy-3-methylglutaryl-coenzyme a reductase-associated autoimmune myopathy","volume":"64","author":"Werner","year":"2012","journal-title":"Arthritis Rheum."},{"key":"ref_253","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1002\/ana.24902","article-title":"Pathogenic role of anti-signal recognition protein and anti-3-hydroxy-3-methylglutaryl-coa reductase antibodies in necrotizing myopathies: Myofiber atrophy and impairment of muscle regeneration in necrotizing autoimmune myopathies","volume":"81","author":"Allenbach","year":"2017","journal-title":"Ann. Neurol."},{"key":"ref_254","doi-asserted-by":"crossref","first-page":"30328","DOI":"10.1074\/jbc.M112.383109","article-title":"Calmodulin-binding locations on the skeletal and cardiac ryanodine receptors","volume":"287","author":"Huang","year":"2012","journal-title":"J. Biol. Chem."},{"key":"ref_255","doi-asserted-by":"crossref","first-page":"3792","DOI":"10.1038\/ncomms4792","article-title":"Endoplasmic reticulum calcium release through itpr2 channels leads to mitochondrial calcium accumulation and senescence","volume":"5","author":"Wiel","year":"2014","journal-title":"Nat. Commun."},{"key":"ref_256","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.atherosclerosis.2010.11.039","article-title":"The relationship of vitamin d deficiency to statin myopathy","volume":"215","author":"Gupta","year":"2011","journal-title":"Atherosclerosis"},{"key":"ref_257","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.chembiol.2013.12.016","article-title":"Vitamin d metabolism, mechanism of action, and clinical applications","volume":"21","author":"Bikle","year":"2014","journal-title":"Chem. Biol."},{"key":"ref_258","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/eci.12698","article-title":"Effect of statins on serum vitamin d concentrations: A systematic review and meta-analysis","volume":"47","author":"Mazidi","year":"2017","journal-title":"Eur. J. Clin. Investig."},{"key":"ref_259","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1124\/mol.60.6.1399","article-title":"Transcriptional control of intestinal cytochrome P-4503A by 1\u03b1,25-Dihydroxy vitamin D3","volume":"60","author":"Thummel","year":"2001","journal-title":"Mol. Pharmacol."},{"key":"ref_260","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jsbmb.2012.09.012","article-title":"Interplay between vitamin d and the drug metabolizing enzyme CYP3A4","volume":"136","author":"Wang","year":"2013","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"ref_261","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.bcp.2012.03.017","article-title":"Intestinal CYP3A4 and midazolam disposition in vivo associate with vdr polymorphisms and show seasonal variation","volume":"84","author":"Thirumaran","year":"2012","journal-title":"Biochem. Pharmacol."},{"key":"ref_262","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/clpt.2008.165","article-title":"Effects of vitamin d supplementation in atorvastatin-treated patients: A new drug interaction with an unexpected consequence","volume":"85","author":"Schwartz","year":"2009","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_263","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.atherosclerosis.2016.11.027","article-title":"Low serum vitamin d, statin associated muscle symptoms, vitamin d supplementation","volume":"256","author":"Glueck","year":"2017","journal-title":"Atherosclerosis"},{"key":"ref_264","doi-asserted-by":"crossref","first-page":"156","DOI":"10.4103\/1947-2714.179133","article-title":"Safety of 50,000-100,000 units of vitamin d3\/week in vitamin D-Deficient, hypercholesterolemic patients with reversible statin intolerance","volume":"8","author":"Jetty","year":"2016","journal-title":"N. Am. J. Med. Sci."},{"key":"ref_265","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1177\/0897190016674407","article-title":"Rechallenging statin therapy in veterans with statin-induced myopathy post vitamin d replenishment","volume":"30","author":"Kang","year":"2017","journal-title":"J. Pharm. Pract."},{"key":"ref_266","doi-asserted-by":"crossref","first-page":"207","DOI":"10.5551\/jat.RV17030","article-title":"Diagnosis and management of statin intolerance","volume":"26","author":"Alonso","year":"2019","journal-title":"J. Atheroscler. Thromb."},{"key":"ref_267","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1016\/j.jacl.2014.03.004","article-title":"The National Lipid Association\u2019s Muscle Safety Expert Panel. An assessment by the statin muscle safety task force: 2014 update","volume":"8","author":"Rosenson","year":"2014","journal-title":"J. Clin. Lipidol."},{"key":"ref_268","doi-asserted-by":"crossref","first-page":"526","DOI":"10.7326\/0003-4819-158-7-201304020-00004","article-title":"Discontinuation of statins in routine care settings: A cohort study","volume":"158","author":"Zhang","year":"2013","journal-title":"Ann. Intern. Med."},{"key":"ref_269","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1345\/aph.1R509","article-title":"Intermittent nondaily dosing strategies in patients with previous statin-induced myopathy","volume":"47","author":"Keating","year":"2013","journal-title":"Ann. Pharmacother."},{"key":"ref_270","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_271","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1016\/j.jacc.2014.03.019","article-title":"Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: The GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab","volume":"63","author":"Stroes","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_272","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1016\/j.amjcard.2019.08.016","article-title":"Characteristics and outcomes of patients treated with proprotein convertase subtilisin\/kexin type 9 inhibitors (the mayo clinic experience)","volume":"124","author":"Oren","year":"2019","journal-title":"Am. J. Cardiol."},{"key":"ref_273","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1177\/1060028018771670","article-title":"The role of PCSK9 inhibitors in the treatment of hypercholesterolemia","volume":"52","author":"Patel","year":"2018","journal-title":"Ann. Pharmacother."},{"key":"ref_274","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1002\/cpt.602","article-title":"Implementing pharmacogenomics in europe: Design and implementation strategy of the ubiquitous pharmacogenomics consortium","volume":"101","author":"Cecchin","year":"2017","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_275","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1056\/NEJMoa1803917","article-title":"Safety and efficacy of bempedoic acid to reduce LDL cholesterol","volume":"380","author":"Ray","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_276","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1161\/CIRCULATIONAHA.118.034710","article-title":"Effect of an siRNA therapeutic targeting PCSK9 on atherogenic lipoproteins","volume":"138","author":"Ray","year":"2018","journal-title":"Circulation"},{"key":"ref_277","doi-asserted-by":"crossref","first-page":"e016604","DOI":"10.1136\/bmjopen-2017-016604","article-title":"Study protocol for statin web-based investigation of side effects (statinwise): A series of randomised controlled N-of-1 trials comparing atorvastatin and placebo in UK primary care","volume":"7","author":"Herrett","year":"2017","journal-title":"BMJ Open"},{"key":"ref_278","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1038\/nature25979","article-title":"Extensive impact of non-antibiotic drugs on human gut bacteria","volume":"555","author":"Maier","year":"2018","journal-title":"Nature"},{"key":"ref_279","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1038\/s41598-017-19013-2","article-title":"Effect of atorvastatin on the gut microbiota of high fat diet-induced hypercholesterolemic rats","volume":"8","author":"Khan","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_280","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.atherosclerosis.2019.07.023","article-title":"Functional role of gut microbiota and PCSK9 in the pathogenesis of diabetes mellitus and cardiovascular disease","volume":"289","author":"Morelli","year":"2019","journal-title":"Atherosclerosis"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/9\/1\/22\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:44:12Z","timestamp":1760190252000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/9\/1\/22"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,20]]},"references-count":280,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,1]]}},"alternative-id":["jcm9010022"],"URL":"https:\/\/doi.org\/10.3390\/jcm9010022","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,20]]}}}